Pharma R&D Today

Wearables in Clinical Trials: Many Benefits, and One Big Challenge

Posted on July 19th, 2017 by Tim Hoctor

The rapid development of wearable technology has the power to be a game-changer in many areas, including pharmaceutical R&D. Its most obvious use for pharma is in clinical trials, where recruiting is a frequent challenge, as is getting study participants to adhere to their therapeutic regime. Continue reading “Wearables in Clinical Trials: Many Benefits, and One Big Challenge” »

The certainty of uncertainty

Posted on July 17th, 2017 by Dr Andrew A. Parsons

The recent election results in France and the UK once again show that a week is a long time in politics. Who would have thought when the UK voted to Brexit that Emmanuel Macron would sweep into power following the creation of his new political party in April 2016? Continue reading “The certainty of uncertainty” »

Precise Medicines: Matching Patients with the Most Effective Drugs

Posted on July 14th, 2017 by Dr. Anton Yuryev

Precision medicine is making us re-think the way we treat disease. Rather than selecting therapies based solely on the disease itself, doctors are increasingly considering the patient’s unique genomic and molecular make-up when determining treatment. Continue reading “Precise Medicines: Matching Patients with the Most Effective Drugs” »

Developing Child-Friendly Drugs

Posted on July 12th, 2017 by Betsy Davis

In a recent article titled A Spoonful of Kids’ Medicine Makes the Profits Go Up, Kaiser Health News reporter Shefali Luthra wrote about how some pharma industry players may view the need for child-friendly versions of drugs as a “lucrative opportunity”. Luthra specifically cited the opportunities presented by laws like the Best Pharmaceuticals for Children Act Continue reading “Developing Child-Friendly Drugs” »

Biosimilars Development & its Future

Posted on July 10th, 2017 by Dr. Makarand Jawadekar, Ph.D

The pharmaceutical industry had really been quite optimistic as of late regarding regulatory overhaul and getting rid of the ever-present ‘red tape’ within the regulatory body in the US, and the FDA had shown a very positive response towards getting biosimilars approved. Continue reading “Biosimilars Development & its Future” »

Advantages and Challenges of Using Social Media for Pharma R&D

Posted on July 7th, 2017 by Betsy Davis

Social media is a force to be reckoned with in modern society. Over the last decade, it has changed the way we interact with friends and family, consumes news and entertainment, and do business.

Continue reading “Advantages and Challenges of Using Social Media for Pharma R&D” »

About this Blog

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.